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ABSTRACT  
Diabetes mellitus emerges from multiple biochemical and cellular impairments, including decreased insulin secretion from the pancreatic β-
cells and impaired insulin action in peripheral tissues. The present study was systematically carried out to evaluate antidiabetic and  
antidyslipidemic properties of GOA-111,a herbal extract containing a mixture of Gymnema sylvestrae, Ocimum sanctum leaves and seed kernel of 
Azadirachta indica  in the ratio of 1:1:1 in ameliorating both the primary and secondary complications of type 2 diabetes mellitus in high fat diet 
fed low dose streptozotocin induced diabetic rats. Experimental type 2 diabetes was induced with a low dose streptozotocin in rats  fed on a 
high fat diet. Diabetic rats were treated with three different doses GOA 111  (150,300 and 450 mg/Kg b.wt/rat/day)   for 30 days. The 
toxicological parameters such as AST, ALT and ALP were assayed. Biochemical parameters such as fasting blood glucose, glycosylated 
hemoglobin, insulin, insulin resistance and lipid profile were measured.  Oral treatment with GOA 111 significantly decreased the elevated 
levels of fasting glucose, glycosylated hemoglobin, AST, ALT and ALP. The insulin level was improved in insulin resistant dia betic rats.  GOA 111 
also normalized the lipid profile. Though the  results showed a dose dependent impact on the parameters, a dose of  300mg/Kg B/W/rat/day 
GOA 111 exerts maximum potential anti-hyperglycemic and antidyslipidemic effects in HFD/STZ-induced type 2 diabetic rats. 
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INTRODUCTION 
Type 2 diabetes mellitus which is caused due to insulin 
resistance is closely related to obesity and sedentary life 
style.  Type2 diabetic individuals are more prone to develop 
both microvascular  and macrovascular complications1. 
Insulin resistance and impaired insulin secretion are the 
core defects in T2DM; however other pathophysiological 
conditions ultimately results in the dysregulation of glucose 
metabolism. Though, the available therapeutic measures for 
the treatment of T2DM are sufficient, search for drugs that 
improve insulin sensitivity, diminish pancreatic β-cell 
dysfunction without any detrimental side effects is 
necessary. 
Natural compounds preferentially from plant sources 
provide various pharmacological effects due to the presence 
of phytochemicals 2. Plant based drugs are more affordable 
and effective with less side-effects when compared to other 
therapies. Pharmaceutical research is increasingly leaning 
towards the discovery of new antidiabetic drugs from 
natural products targeting pathways or components 
associated with type 2 diabetes mellitus (T2DM) 
pathophysiology3. Herbal remedies are preferred in 
traditional systems of medicine, despite the fact of less 
scientific evaluation for their toxicity and efficacy. Though, a 
number of individual herbs have been experimentally 
reported to exert antidiabetic effects, limited studies have 
been carried out on polyherbal formulations. Herbal 
compounds contain a combination of several plant products 
which possess synergistic antidiabetic effects to enhance the 
desired pharmacological actions 4.  
G. sylvestre is one of the indispensable medicinal plants used 
in Ayurvedic system of medicine for the treatment of diverse 
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diseases. It is used in food additives against obesity 5,6.  
Ocimum sanctum belongs to the family of Lamiaceae and is 
commonly known as Thulasi/Tulsi in India. It is widely 
grown in all regions and is considered as the sacred plant of 
India. In the Indian sub-continent, fresh leaves of this plant 
are most commonly used for the treatment of cough, cold, 
abdominal pain, skin diseases, arthritis, painful eye diseases, 
measles, and diarrhea. The preclinical evaluation on various 
extracts of different parts of Ocimum sanctum showed 
antioxidant, anti-cancer, anti-diabetic, anti-bacterial, 
hepatoprotective and cardioprotective actions7,8,9,10,11. 
Azadirachta indica, commonly known as neem, has attracted 
worldwide prominence in recent years, owing to its wide 
range of medicinal properties. Neem has been extensively 
used in Ayurveda, Unani and Homoeopathic medicine and 
has become a cynosure of modern medicine12.  The tree and 
its extracts have also been reported to possess insecticidal, 
anti-viral, anti-fungal and anti-bacterial properties13.   
In view of the above reported medicinal properties, the 
present study was designed to evaluate the antidiabetic and 
antidyslipidemic properties of a mixture of G.sylvestrea, 
O.sanctum and  A.indica (GOA 111) in high fat fed low dose 
streptozotocin induced type 2 diabetic rats. 
MATERIALS AND METHODS 
Plant Material 
A mixture of the leaves of G.sylvestrea, O.sanctum and the 
seed kernel of A.indica in the ratio of  1:1:1, was used in the 
present study. 
Experimental Animals 
Male albino wistar rats weighing 150-170g were purchased 
and maintained in Nandha College of Pharmacy, Erode. The 
rats were housed in polypropylene cages lined with husk. 
They were maintained at an ambient temperature of 25 ± 2˚c 
and 12/12 h of light/dark cycle. Animals were fed with 
standard commercial rat chow (Hindustan Lever Ltd) and 
water ad libitum and housed under standard environmental 
conditions throughout the study. The experiments were 
strictly conducted according to the ethical norms approved 
by the Ministry of Social Justices and Empowerment, 
Government of India and Institutional Animal Ethics 
Committee Guidelines [IAECNO:  NCP/IAEC/2018-19/19 ]. 
High fat diet fed streptozotocin induced diabetes 
The rats were divided into two dietary regimens by feeding 
either normal or high fat diet (HFD) for the initial period of 
two weeks14. The composition of HFD is powdered NPD – 
365g/kg, Lard – 310 g/kg, Caseine – 250g/kg, cholesterol – 
10g/kg, vitamin and mineral mix – 60g/kg, DL-methionine – 
3g/kg, Yeast powder – 1g/kg, NaCl – 1g/kg. After two weeks 
of dietary manipulation, the groups of rats fed with HFD was 
injected intraperitoneally (IP) with a low dose of STZ (35 
mg/kg b.w) dissolved in 0.1M cold citrate buffer, pH 4.5). 
One week after STZ injection, the rats were screened for 
blood glucose level. Rats having fasting blood glucose (FBG) 
>250mg/dl that exhibited random hyperglycaemia and 
glycosuria were selected for the experiment. The rats 
continued to feed on their respective diets until the end of 
the experiments.  
Designing of Experimental Animals 
The rats were divided into six groups (n=6):  
Group I –  Control rats. 
Group II –  HFD fed - low dose STZ induced type 2 
diabetic rats. 
Group III –  Diabetic rats orally treated with GOA-
1:1:1(150 mg/ kg b.w./rat/day). 
Group IV        – Diabetic rats orally treated with GOA-
1:1:1(300 mg/ kg b.w./rat/day).  
Group V          - Diabetic rats orally treated with GOA-
1:1:1(450 mg/ kg b.w./rat/day).  
Group VI        -    Diabetic rats orally treated with a standard 
drug, metformin (50 mg/ kg b.w./rat/day) in aqueous 
solution. 
At the end of the treatment period, the rats were allowed to 
fast overnight before they were anesthetized and sacrificed 
by cervical decapitation. The blood was collected with and 
without anticoagulants for plasma and serum separation, 
respectively.  
Oral Glucose Tolerance Test 
 Oral glucose tolerance test (OGTT) test was performed in all 
the groups of animals on the day prior to sacrifice. Blood 
samples were obtained from the lateral tail vein of rat. 
Successive blood sample was taken at 0, 30, 60, 90 and 120 
minutes following the administration of 2 g/kg b.w. of 
glucose solution. 
Biochemical parameters 
Glucose was measured by glucose oxidase method15. Plasma 
was separated and used for insulin assay using ELISA kit for 
rats (Linco Research, Inc., USA). Levels of hemoglobin and 
glycosylated hemoglobin were estimated according to 
methods of Drabkin and Austin, 1932; Nayak and 
Pattabiraman, (1981) respectively16,17.  
Aspartate transaminase(AST), Alanine transaminase 
(ALT)and Alkaline phosphatase (ALP) were assayed by the 
method of King 18a,b.  
Determination of homeostasis model of insulin assessment 
Insulin abnormality cannot be accurately detected by a 
single determination of insulin or glucose levels. Hence, 
insulin resistance was evaluated by homeostasis model 
assessment of insulin resistance (HOMA-IR)19. 
HOMA-IR = Fasting insulin level (µU/ml) X Fasting blood 
glucose (mg/dl) / 405 
Lipid profile studies 
Cholesterol content, triglycerides, and free fatty acids in 
serum tissues were estimated 20.21.22. Phospholipid 
concentration was estimated by the method of Bartlett23 by 
digestion with perchloric acid and the phosphate liberated 
was estimated by the method of Fiske and Subbarow24.   
Statistical analysis 
The results were expressed as mean ± S.E.M of six rats per 
group and statistical significance was evaluated by one-way 
analysis of variance (ANOVA) using SPSS (version 16) 
program followed by LSD. Values were considered 
statistically significant when p < 0.05. 
RESULTS AND DISCUSSION 
The development of animal model for type 2 diabetes which 
reflect the natural metabolic characteristics of human T2DM 
is very challenging. Feeding high fat diet results in insulin 
resistance 25. Furthermore, administration of low dose STZ 
mediates mild impairment to pancreatic β-cells which is 
parallel to the metabolic characteristics of the later stage of 
T2DM.  A combination of HFD and low dose of STZ (45 
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mg/kg) injection is used to generate a rat model that mimics 
the clinical features of type-2 diabetes in humans26. 
Metformin, an oral antidiabetic drug acts primarily at the 
liver by reducing glucose output and, secondarily, by 
facilitating glucose uptake in the peripheral tissues, chiefly 
in muscle27.  Hence, in the present study, metformin was 
used as a standard drug to compare the efficacy of the GOA 
111 in ameliorating hyperglycemia and its associated 
complications. 
The levels of blood glucose in certain durations after the oral 
administration of glucose (2g/Kg body weight) in normal 
and experimental group of rats is depicted in Figure 1.
 
 
FIGURE 1: EFFECT OF GOA 111 ON BLOOD GLUCOSE LEVEL   AFTER RECEIVING AN ORAL GLUCOSE CHALLENGE 
Impaired fasting glucose (IFG) has been commonly 
encountered in primary care since fasting plasma glucose 
test (FG) becomes the most popular screening test for 
diabetes mellitus (DM). Individuals with abnormal glucose 
regulation between normal glucose homeostasis and DM are 
identified, defined by an elevated FG level28. OGTT is a 
measure of effective glucose utilization by the system and it 
is often performed for early diagnosis of diabetes29. It is 
considered as a more sensitive measure of early 
abnormalities in glucose homeostasis than fasting plasma 
glucose or glycosylated hemoglobin.. In control rats, the 
blood glucose level reached the maximum peak at 60 min 
after an oral glucose load and then it was gradually reverted 
back to near normal levels after 120 min. In STZ-induced 
diabetic rats, the peak increase in blood glucose 
concentration was observed after 60 min and remained high 
over the next 60 min. Oral administration of GOA 111 at the 
dosage of 300mg and 450 mg/kg.bw/rat/day to HFD-STZ 
induced diabetic rats showed significant decrease in blood 
glucose concentration at 60 and 120 min when compared 
with diabetic control. However, only a moderate reduction in 
blood glucose levels were observed in the rats treated with 
150mg/kg.bw/rat/day. The marked decrease in the blood 
glucose levels after an oral glucose challenge in diabetic rats 
treated with GOA 111 indicating the beneficial effect of GOA 
111in maintaining glucose homeostasis. 
The effect of GOA 111 on the levels of fasting blood glucose, 
fasting plasma insulin and glycosylated hemoglobin (HbA1c 
%) in HFD/STZ diabetic rats is shown in Table 1. 
 
Table 1: Shows the levels of blood glucose, hemoglobin, glycosylated hemoglobin (HbA1c), plasma insulin and urine 
sugar in control and experimental groups of rats. 
Groups Fasting Blood glucose Hemoglobin HbA1c Insulin Urine sugar 
Control 84.60 ± 2.80 14.50 ± 0.32 6.38 ± 0.15 15.50 ± 0.24 Nil 
Diabetic control 269.90 ± 3.30a* 8.31 ± 0.51a* 13.18. ± 0.20a* 10.38 ± 0.18a* +++ 
Diabetic + GOA 111 
(150mg/Kg.b.w) 
111.00 ± 1.93 b* 11.90 ± 0.39 b* 8.26 ± 0.20b* 11.00 ± 0.28 b* + 
Diabetic + GOA 111 
(300mg/Kg.b.w) 
99.30 ± 2.80 b* 12.61 ± 0.45 b* 7.50 ± 0.14b* 12.40 ± 0.30 b* Nil 
Diabetic + GOA 111 
(450mg/Kg.b.w) 
97.30 ± 2.73 b* 12.50 ± 0.46 b* 7.60 ± 0.17b* 12.43 ± 0.24 b* Nil 
Diabetic+metformin 88.00 ± 2.10b* 13.50 ± 0.39 b* 7.00 ± 0.19b* 13.55 ± 0.29 b* Nil 
Units: mg/dl for blood glucose, g/dl for hemoglobin, % hemoglobin for HbA1c, µU/ml for plasma insulin, +++ indicates more 
than 2% sugar.  Results are expressed as mean ± S.E.M [n=6]. One-way ANOVA followed by post hoc test LSD. Values are 
statistically significant at @ P<0.05; #P<0.01; *P<0.001. The results were compared with aControl rats, bDiabetic rats, 
cDiabetic rats treated with metformin.  
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Values are given as mean ± SEM for groups of six rats in each. One way ANOVA followed by post hoc test LSD.  
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The levels of blood glucose and HbA1c % were found to be 
significantly elevated in diabetic rats as compared with 
normal control. Oral administration of GOA 111 to diabetic 
rats significantly   improved the altered level. The levels of 
plasma insulin were moderately decreased in HFD-STZ 
induced diabetic rats. Diabetic rats treated with GOA 
111(300mg and 450mg/kg b.w) and metformin showed 
improved insulin level.  
Control rats did not show any significant variation in the 
blood glucose concentration throughout the experimental 
period. HFD-STZ induced diabetes results in chronic 
hyperglycemia, which was maintained throughout 
experimental period. In experimental rats, the levels of 
blood glucose, glycosylated hemoglobin were increased and 
the levels of hemoglobin, plasma insulin were decreased 
when compared with control group of rats. Upon oral 
administration with GOA 111 and metformin, these levels 
were reverted back to those of normal rats. Urine sugar 
which was present in the diabetic group of rats was found to 
be absent in GOA 111 as well as metformin treated groups of 
rats. 
Glucose is an indispensable fuel for all cells and organs, but 
at the same time it leads to problems at high concentrations. 
As a consequence, blood glucose is controlled in a narrow 
range to guarantee constant supply and to avoid damages 
associated with elevated glucose levels. Liver is the main 
organ controlling blood glucose by (i) releasing newly 
synthesized or stored glucose in the blood stream when 
blood glucose is low, and (ii) using and storing glucose when 
blood glucose is elevated30.In the liver, defects in insulin-
stimulated hepatic glycogen synthesis and increased rates of 
hepatic gluconeogenesis are the main factors that contribute 
to insulin resistance and fasting hyperglycemia31.The blood 
glucose levels are significantly increased in diabetic group of 
rats which results from reduced glucose utilization by 
various tissues, which is a typical condition of 
insulinopenic32.A significant decrease in FBG levels in GOA 
111 treated diabetic rats indicated that the GOA 111 has 
improved the insulin resistance in HFD-STZ induced diabetic 
rats  
The HbA1c value reflects the average blood glucose over a 2-
3 month period and has traditionally been used to evaluate 
the treatment of established DM. It has been described as a 
predictor for DM and of micro- and macrovascular disease 
33,34,35,36. The HbA1c levels are the most reliable markers to 
assess the glycemic status of diabetic individuals over a 
period of 2- 3 month and prognostic value of the 
treatment37. Oral treatment with GOA 111 to diabetic rats 
significantly reduced the levels of HbA1c suggesting the 
beneficial effect of GOA 111 in maintaining glucose 
homeostasis. 
Homeostatic model assessment (HOMA) is a method used to 
quantify insulin resistance and beta-cell function. HOMA-IR 
revealed impaired insulin tolerance in diabetic rats, which is 
associated with hyperinsulinemia. In type 2 diabetes, insulin 
resistance is a major factor that contributes to 
hyperinsulinemia and impaired insulin secretion. Due to 
decreased  insulin response, β cells secrete more insulin in 
response to the persistent hyperglycemia, resulting in 
hyperinsulinemia 38. In the present study, HOMA IR value 
was reduced in diabetic rats treated with GOA 111 indicating 
improved insulin sensitivity. Figure 2 represents the effect of 
GOA 111 in lowering the  insulin resistance in the different 
groups of rats. The results show significance both within the 
groups and between the groups. 
 
 
 
Figure 2 : HOMA-IR of control, diabetic, diabetic treated with GOA 111 and metformin groups of rats  
 
Results are expressed as mean ± S.E.M [n=6]. One-way ANOVA followed by post hoc test LSD. Statistical significance was 
compared within the groups as follows: 
a
control rats; 
b
diabetic control rats. Values are statistically significant at 
*
p<0.05 
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Table 2 represents the effect of GOA 111 on the activities of 
serum AST, ALT and ALP in the experimental groups of rats. 
The pathophysiological indices in diabetic group of rats were 
significantly (p < 0.05) elevated as compared with control 
group of rats. Oral administration of GOA 111 to diabetic 
groups of rats significantly (p < 0.05) normalized the altered 
levels in comparison with control group of rats. The results 
are comparable with the standard drug metformin. 
 
Table 2:  Effect of GOA 111on the levels of activities of aspartate aminotransferase (AST), alanine aminotransferase 
(ALT) and alkaline phosphatase (ALP) in serum, liver and kidney tissues of control and experimental groups of rats. 
Groups AST ALT ALP 
Control 87.21 ± 3.10 20.44 ± 0.96 75.10 ± 3.10 
Diabetic control 129.00 ± 7.11a* 46.10 ± 1.80a* 138.00 ± 4.00a* 
Diabetic + GOA 111 
(150mg/Kg.b.w) 
95.61 ± 4.00b* 26.22 ± 1.39 b* 84.00 ± 3.14b* 
Diabetic + GOA 111 
(300mg/Kg.b.w) 
91.00. ± 3.18b* 25.16 ± 1.50b* 81.30 ± 3.2b* 
Diabetic + GOA 111 
(450mg/Kg.b.w) 
90.00. ± 3.24b* 25.00 ± 1.40 b* 80.10 ± 3.00b* 
Diabetic+metformin 89.00 ± 2.90 b* 22.21 ± 1.38 b* 78.11 ± 2.80 b* 
 
Liver, the key organ of metabolism and excretion, performs 
detoxification of xenobiotics, environmental pollutants, and 
chemotherapeutic agents. AST, ALT, ALP, are the major 
hepatic marker enzymes. The increased level of these 
enzymes is due to leakage from hepatocyte damage39. The 
elevation in AST and ALT activity can be regarded as an 
indicator for gluconeogenesis40.  Oral administration of GOA 
111 decreased AST and ALT levels indicating reduced 
gluconeogenesis. 
The status lipid profile in experimental rats is presented in 
Figure 3.  HFD-STZ diabetic rats showed increase in serum 
cholesterol, triglycerides and FFAs as compared with the 
control group.  Oral treatment of GOA 111 decreased the 
levels of lipid profile.  
Diabetes is associated with profound alterations in the 
plasma lipid and lipoprotein profile and with an increased 
risk of premature atherosclerosis, coronary insufficiency and 
myocardial infarction41. Hyperglycemia and the high level of 
insulin resistance that are characteristic with T2DM have 
multiple effects on fat metabolism, finally resulting in the 
production of atherogenic dyslipidemia. This is 
characterized by lipoprotein abnormalities: elevated very 
low density lipoprotein cholesterol (VLDL) elevated low 
density lipoprotein cholesterol (LDL-c), elevated 
triacylglycerol (TAG) and decreased high density lipoprotein 
cholesterol (HDL-c) which are measured for cardiovascular 
risk prediction42,43. 
 
 
Figure 3: Effect of GOA 111 on  serum lipid  profile  in  experimental groups of rats 
 
 
0.00
50.00
100.00
150.00
200.00
250.00
Cholesterol Triglycerides Phospholipids Free fatty acids
Serum
Control
Diabetic control
Diabetic + GOA 111
(150mg/kg.b.w)
Diabetic + GOA 111
(300mg/kg.b.w)
Diabetic+GOA 111
(450mg/kgb.w)
Diabetic+Metformin
 
b* 
b* b* 
a* 
b* 
b* 
b* 
a* 
b* 
b* 
b* 
b* 
b* 
b* 
a* 
b* 
a* 
b* 
b* b* 
m
g
/d
l 
Sathyanarayan et al                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):115-121 
ISSN: 2250-1177                                                                                  [120]                                                                                 CODEN (USA): JDDTAO 
The major pathogenesis of lipid metabolism disturbances in 
diabetes is the enhanced mobilization of free fatty acids from 
adipose tissue and secondary elevation of free fatty acid 
level in the blood44, as observed in the present study.  The 
elevated level of serum lipids in diabetics is essentially due 
to increase in the mobilization of free fatty acids from the 
peripheral depots, since insulin inhibits the activity of 
hormone sensitive lipase. On the other hand, glucagon, 
catecholamines and other hormones enhance the lipolysis. 
Treatment with the GOA 111to diabetic rats resulted in the 
correction of hyperlipidemia and this may be attributed to 
the enhanced glucose utilization indicating its 
antidyslipidemic nature. 
CONCLUSION 
The results of the present study indicate that GOA 111 
possesses antidiabetic and antidylipidemic properties. 
Polyherbal formulations having a mixture of several 
phytoingredients at various proportions  from plant origin 
are often preferred because of their availability, accessibility, 
affordability, stability and safety. It is well understood that 
the mixture of various phytoingredients present in GOA 111 
are claimed to display synergistic and efficacious actions and 
the mixture of species in them shows better therapeutic 
effect relatively at a lesser concentration than either species 
on its own.  
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